基因组特征揭示在非上呼吸消化道自然杀伤/T细胞淋巴瘤治疗中加入抗PD-1免疫治疗的可能获益
该研究评估了14家医院1589例新诊断自然杀伤/T细胞淋巴瘤(NKTCL)患者,其中196例(12.3%)为非上呼吸消化道NKTCL(NUAT-NKTCL),具有不良临床特征和较差预后。全基因组和全外显子测序显示NUAT-NKTCL与上呼吸消化道NKTCL突变谱显著不同,基因组不稳定性更高。在NUAT-NKTCL队列中,128例接受一线P-GEMOX化疗,其中37例联合抗PD-1免疫治疗,匹配队列分析显示联合抗PD-1显著改善3年无进展生存率(53.9% vs 17.0%,P=0.009)和3年总生存率(63.7% vs 29.2%,P=0.01)。
要点
- NUAT-NKTCL占新诊断NKTCL的12.3%,临床特征不良且预后较差。
- NUAT-NKTCL较UAT-NKTCL基因组不稳定性显著更高,突变谱明显不同。
- 一线P-GEMOX联合抗PD-1较单用化疗改善NUAT-NKTCL的3年PFS和OS。
核心结论
- NUAT-NKTCL与UAT-NKTCL具有不同的临床特征和突变谱。
- 在NUAT-NKTCL一线治疗中加入抗PD-1免疫治疗可能获益。
- 需进一步研究验证免疫化疗的疗效和相关生物标志物。
研究设计与样本
- 研究纳入14家医院1589例新诊断NKTCL患者,其中196例(12.3%)为NUAT-NKTCL。
- 采用全基因组测序(WGS)和全外显子测序(WES)分析突变谱。
- NUAT-NKTCL队列中128例接受一线P-GEMOX化疗,37例联合抗PD-1免疫治疗。
主要发现
- NUAT-NKTCL患者具有不良临床特征和较差预后。
- NUAT-NKTCL较UAT-NKTCL基因组不稳定性显著更高,突变谱明显不同。
- 匹配的NUAT-NKTCL队列中,联合抗PD-1组3年PFS率53.9% vs 单用化疗组17.0%(P=0.009)。
- 联合抗PD-1组3年OS率63.7% vs 单用化疗组29.2%(P=0.01)。
- WES显示免疫化疗应答者中免疫调节和基因组不稳定性相关突变频繁。
关键数值与推荐
- NUAT-NKTCL占新诊断NKTCL的196/1589(12.3%)。
- 联合抗PD-1组3年PFS率53.9% vs 单用化疗组17.0%(P=0.009)。
- 联合抗PD-1组3年OS率63.7% vs 单用化疗组29.2%(P=0.01)。
临床怎么用
- 作者建议在NUAT-NKTCL一线治疗中加入抗PD-1免疫治疗。
- 作者指出需进一步研究验证免疫化疗的疗效和相关生物标志物。
局限性
- 原文指出需进一步研究验证本研究所提出的免疫化疗的疗效和相关生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Natural killer/T-cell lymphoma (NKTCL) is a highly heterogeneous disease with a poor prognosis. However, the genomic characteristics and proper treatment strategies for non-upper aerodigestive tract NKTCL (NUAT-NKTCL), a rare subtype of NKTCL, remain largely unexplored. In this study, 1589 patients newly diagnosed with NKTCL at 14 hospitals were assessed, 196 (12.3%) of whom had NUAT-NKTCL with adverse clinical characteristics and an inferior prognosis. By using whole-genome sequencing (WGS) and whole-exome sequencing (WES) data, we found strikingly different mutation profiles between upper aerodigestive tract (UAT)- and NUAT-NKTCL patients, with the latter group exhibiting significantly higher genomic instability. In the NUAT-NKTCL cohort, 128 patients received frontline P-GEMOX chemotherapy, 37 of whom also received anti-PD-1 immunotherapy. The application of anti-PD-1 significantly improved progression-free survival (3-year PFS rate 53.9% versus 17.0%, P = 0.009) and overall survival (3-year OS rate 63.7% versus 29.2%, P = 0.01) in the matched NUAT-NKTCL cohort. WES revealed frequent mutations involving immune regulation and genomic instability in immunochemotherapy responders. Our study showed distinct clinical characteristics and mutational profiles in NUAT-NKTCL compared with UAT patients and suggested adding anti-PD-1 immunotherapy in front-line treatment of NUAT-NKTCL. Further studies are needed to validate the efficacy and related biomarkers for immunochemotherapy proposed in this study.
引用
- Chen Z, Huang H, Huang H, et al. Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma. Leukemia. 2024. PMID: 38378844. doi:10.1038/s41375-024-02171-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。